The drug screening market is expected to reach USD 8.63 Billion by 2022 from USD 5.32 Billion in 2017, at a CAGR of 10.2%.
Factors such as growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and the availability of government funding in major markets are driving the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773
Drug screening market segmentation:
• based on products
• based on diseases
• based on techniques,
• based on end users
• based on regions.
The Major Players Opearting in the Drug screening Market:
Most key players adopted product launches as the primary growth strategy between 2014 and 2017. Some of the companies that adopted this strategy include Alfa Scientific Designs, Thermo Fisher, and Premier Biotech.
Geographical Detailed Analysis for Drug screening Market:
North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug addiction, presence of laws supporting drug screening, and growing burden of road accidents due to alcohol consumption in the region.
The drug screening market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market include Alere (US), Thermo Fisher (US), Siemens Healthineers (Germany), Alfa Scientific Designs (US), Roche (Switzerland), MPD, Inc. (US), Shimadzu (Japan), OraSure (US), Lifeloc (US), and Drägerwerk (Germany). On the other hand, LabCorp (US), Quest Diagnostics (US), Psychemedics (US), Omega Laboratories (US), CRL (US), SureHire (Canada), and CannAmm (Canada).
Read More in Detailed (Drug screening Market ): https://www.marketsandmarkets.com/PressReleases/drug-alcohol-screening.asp
